Therapy » Gilbert’s syndrome concerning a new look at the effects of hyperbilirubinemia

Gilbert’s syndrome concerning a new look at the effects of hyperbilirubinemia

DOI: https://dx.doi.org/10.18565/therapy.2024.3.88-93

Gerasimenko I.V., Morozov N.T., Gerasimenko A.A.
N.P. Ogarev National Research Mordovia State University, Saransk

Abstract. Previously, bilirubin was considered as a potentially dangerous waste product of the vital activity of the organism, and Gilbert’s syndrome, characterized by moderate increase in unconjugated bilirubin systemic level, was perceived as a pathological condition requiring correction of hyperbilirubinemia. However, recent research works show that bilirubin molecule serves as a modulator of various biological functions in the body and has powerful antioxidant and anti-inflammatory properties, immunomodulatory and antiproliferative effects, and the ability to regulate metabolism with obvious clinical and even therapeutic implications. That is why, moderate hyperbilirubinemia can be considered as protection against the development of a wide range of “diseases of civilization”. The review analyzes the results of current studies showing new properties of bilirubin and the mechanisms of their implementation, as well as the possible clinical significance of hyperbilirubinemia with formation of a new viewpoint at Gilbert’s syndrome.

Keywords: modulator of metabolism, antiproliferative and anti-inflammatory properties, antioxidant immunomodulatory, bilirubin, Gilbert’s syndrome

Read entire article

Literature

1. Vítek L., Tiribelli C. Bilirubin: The yellow hormone? J Hepatol. 2021; 75(6): 1485–90.

https://doi.org/10.1016/j.jhep.2021.06.010. PMID: 34153399.

2. Jangi S., Otterbein L., Robson S. The molecular basis for the immunomodulatory activities of unconjugated bilirubin. Int J Biochem Cell Biol. 2013; 45(12): 2843–51.

https://doi.org/10.1016/j.biocel.2013.09.014. PMID: 24144577.

3. Wu Y., Li M., Xu M. et al. (2011). Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes. 2011; 3(3): 217–24.

https://doi.org/10.1111/j.1753-0407.2011.00138.x. PMID: 21631904.

4. Cui Y., Wu C., Li L. et al. Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases. Materials Today Bio. 2023; 20: 100658.

https://doi.org/10.1016/j.mtbio.2023.100658. PMID: 37214553. PMCID: PMC10196858.

5. Baranano D.E., Rao M., Ferris C.D., Snyder S.H. Biliverdin reductase: A major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002; 99(25): 16093–98.

https://doi.org/10.1073/pnas.252626999. PMID: 12456881. PMCID: PMC138570.

6. Huang Y., Li J., Li W. et al. Biliverdin/bilirubin redox pair protects lens epithelial cells against oxidative stress in age-related cataract by regulating NF-kappaB/iNOS and Nrf2/HO-1 pathways. Oxid Med Cell Longev. 2022; 2022: 7299182.

https://doi.org/10.1155/2022/7299182. PMID: 35480872. PMCID: PMC9036166.

7. Yao Q., Sun R., Bao S. et al. Bilirubin protects transplanted islets by targeting ferroptosis. Front Pharmacol. 2020; 11: 907.

https://doi.org/10.3389/fphar.2020.00907. PMID: 32612533. PMCID: PMC7308534.

8. Saha S., Buttari B., Panieri E. et al. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020; 25(22): 5474.

https://doi.org/10.3390/molecules25225474. PMID: 33238435. PMCID: PMC7700122.

9. Stocker R., Yamamoto Y., McDonagh A.F. et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987; 235(4792): 1043–46.

https://doi.org/10.1126/science.3029864. PMID: 3029864.

10. Novak P., Jackson A.O., Zhao G.J., Yin K. Bilirubin in metabolic syndrome and associated inflammatory diseases: New perspectives. Life Sci. 2020; 257: 118032.

https://doi.org/10.1016/j.lfs.2020.118032. PMID: 32621920.

11. Basiglio C.L., Arriaga S.M., Pelusa H.F. et al. Protective role of unconjugated bilirubin on complement-mediated hepatocytolysis. Biochim Biophys Acta. 2007; 1770(7): 1003–10.

https://doi.org/10.1016/j.bbagen.2007.03.005. PMID: 17442495.

12. Vogel M.E., Idelman G., Konaniah E.S., Zucker S.D. Bilirubin prevents atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice by inhibiting endothelial VCAM-1 and ICAM-1 signaling. J Am Heart Assoc. 2017; 6(4): e004820.

https://doi.org/10.1161/JAHA.116.004820. PMID: 28365565. PMCID: PMC5532999.

13. Vítek L., Ostrow J.D. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des. 2009; 15(25): 2869–83.

https://doi.org/10.2174/138161209789058237. PMID: 19754364.

14. Stec D.E., John K., Trabbic C.J. et al. Bilirubin binding to PPARα inhibits lipid accumulation. PLoS One. 2016; 11(4): e0153427.

https://doi.org/10.1371/journal.pone.0153427. PMID: 27071062. PMCID: PMC4829185.

15. Schadinger S.E., Bucher N.L., Schreiber B.M., Farmer S.R. PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab. 2005; 288(6): E1195–205.

https://doi.org/10.1152/ajpendo.00513.2004. PMID: 15644454.

16. Hinds T.D. Jr., Hosick P.A., Chen S. et al. Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα. Am J Physiol Endocrinol Metab. 2017; 312(4): E244–E252.

https://doi.org/10.1152/ajpendo.00396.2016. PMID: 28096081. PMCID: PMC5406988.

17. Wei Y., Liu C., Lai F. et al. Associations between serum total bilirubin, obesity and type 2 diabetes. Diabetol Metab Syndr. 2021; 13(1): 143.

https://doi.org/10.1186/s13098-021-00762-0. PMID: 34876211. PMCID: PMC8650363.

18. Nano J., Muka T., Cepeda M. et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis of observational evidence. Diabetes Metab. 2016; 42(6): 389–97.

https://doi.org/10.1016/j.diabet.2016.06.002.

19. Vítek L., Tiribelli C. Gilbert’s syndrome revisited. J Hepatol. 2023; 79(4): 1049–55.

https://doi.org/10.1016/j.jhep.2023.06.004. PMID: 37390966.

20. DiNicolantonio J.J., McCarty M., Ok J. Does elevated bilirubin aid weight control by preventing development of hypothalamic leptin resistance? Open Heart. 2019; 22;6(1): 6e000897.

https://doi.org/10.1136/openhrt-2018-000897. PMID: 30997121. PMCID: PMC6443125.

21. Takei R., Inoue T., Sonoda N. et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One. 2019; 14(10): e0223302.

https://doi.org/10.1371/journal.pone.0223302. PMID: 31577826. PMCID: PMC6774504.

22. Flack K.D., Vítek L., Fry C.S. et al. Cutting edge concepts: Does bilirubin enhance exercise performance? Front Sports Act Living. 2023; 4: 1040687.

https://doi.org/10.3389/fspor.2022.1040687. PMID: 36713945. PMCID: PMC9874874.

23. Niknama M., Malekia M.H., Khakshourniaab S. et al. Bilirubin, an endogenous antioxidant that affects p53 protein and its downstream apoptosis/autophagy-related genes in LS180 and SW480 cell culture models of colorectal cancer. Biochem Biophys Res Commun. 2023; 672: 161–67.

https://doi.org/10.1016/j.bbrc.2023.06.050. PMID: 37354609.

24. Yuan X., Ma C., Li J. et al. Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS. J Bone Oncol. 2023; 39: 100472.

https://doi.org/10.1016/j.jbo.2023.100472. PMID: 36876225. PMCID: PMC9982672.

25. Vitek L., Bellarosa C., Tiribelli C. Induction of mild hyperbilirubinemia: hype or real therapeutic opportunity? Clin Pharmacol Ther. 2019; 106(3): 568–75.

https://doi.org/10.1002/cpt.1341. PMID: 30588615.

26. Lv X., Xia Y., Finel M. et al. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharm Sin B. 2019; 9(2): 258–78.

https://doi.org/10.1016/j.apsb.2018.09.005. PMID: 30972276. PMCID: PMC6437557.

27. Shibuya A., Itoh T., Tukey R.H., Fujiwara R. Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. Sci Rep. 2013; 3: 2903.

https://doi.org/10.1038/srep02903. PMID: 24104695. PMCID: PMC3793218.

28. Рейзис А.Р., Хохлова О.Н., Никитина Т.С. Синдром Жильбера: современные воззрения, исходы и терапия. Доктор.Ру. 2012; (3): 42–45. (Reizis A.R., Khokhlova O.N., Nikitina T.S. Gilbert’s syndrome: Current insights, outcomes and therapies. Doctor.Ru. 2012; (3): 42–45 (In Russ.)). EDN: PJBPSV.

29. Benaron D.A., Bowen F.W. Variation of initial serum bilirubin rise in newborn infants with type of illness. Lancet. 1991; 338(8759): 78–81.

https://doi.org/10.1016/0140-6736(91)90074-y. PMID: 1676469.

30. Choi Y., Lee S.J., Spiller W. et al. Causal associations between serum bilirubin levels and decreased stroke risk: A two-sample Mendelian randomization study. Arterioscler Thromb Vasc Biol. 2020; 40(2): 437–45.

https://doi.org/10.1161/ATVBAHA.119.313055. PMID: 31801373. PMCID: PMC6975519.

31. Seyed Khoei N., Grindel A., Wallner M. et al. Mild hyperbilirubinaemia as an endogenous mitigator of overweight and obesity: Implications for improved metabolic health. Atherosclerosis. 2018; 269: 306–11.

https://doi.org/10.1016/j.atherosclerosis.2017.12.021. PMID: 29279144.

32. Inoguchi T., Nohara Y., Nojiri C., Nakashima N. Association of serum bilirubin levels with risk of cancer development and total death. Sci Rep. 2021; 11(1): 13224.

https://doi.org/10.1038/s41598-021-92442-2. PMID: 3416820.1 PMCID: PMC8225648.

33. Su Q., Li X., Mo W., Yang Z. Low serum bilirubin, albumin, and uric acid levels in patients with Crohn’s disease. Medicine (Baltim.). 2019; 98(19): e15664.

https://doi.org/10.1097/MD.0000000000015664. PMID: 31083269. PMCID: PMC6531115.

34. Zhou Z.X., Chen J.K., Hong Y.Y. et al. Relationship between the serum total bilirubin and inflammation in patients with psoriasis vulgaris. J Clin Lab Anal. 2016; 30(5): 768–75.

https://doi.org/10.1002/jcla.21936. PMID: 27061381. PMCID: PMC6807132.

About the Autors

Irina V. Gerasimenko, MD, PhD (Medicine), associate professor of the Department of propaedeutics of internal diseases, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevistskaya St.
E-mail: gerasimenkoi@list.ru
ORCID: https://orcid.org/0000-0002-4008-4689
Nikolay T. Morozov, MD, PhD (Medicine), associate professor of the Department of propaedeutics of internal diseases, N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevistskaya St.
E-mail: morozovnt@yandex.ru
Anastasia A. Gerasimenko, student of N.P. Ogarev National Research Mordovia State University. Address: 430005, Saransk, 68 Bolshevistskaya St.
E-mail: anastasiagerasimenko@list.ru

Back to Content